DMAC insider boosts direct holdings to 87,854 shares via option exercise

Rhea-AI Filing Summary

DiaMedica Therapeutics Inc. (DMAC) director reports stock option exercise. A company director exercised a stock option to acquire 12,000 common shares of DiaMedica on 11/21/2025 at an exercise price of $2.20 per share, with the price shown after converting the original CAD$ exercise price to US$ on the transaction date. Following this transaction, the director directly owns 87,854 common shares of DiaMedica. The derivative position reported was a stock option (right to buy) for 12,000 shares that was fully vested and, after the exercise, the number of derivative securities beneficially owned is reported as 0.

Insider Trade Summary

12,000 shares exercised/converted

Mixed 2 txns

Insider Parsons James T.

Role Director

Type	Security	Shares	Price	Value
Exercise	Stock Option (right to buy)	12,000	$0.00	--
Exercise	Common Stock	12,000	$2.20	$26K

Holdings After Transaction: Stock Option (right to buy) — 0 shares (Direct); Common Stock — 87,854 shares (Direct)

Footnotes (1)

1. Represents the conversion of the exercise price from CAD$ to US$ on the transaction date. Fully vested.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Parsons James T.

(Last) (First) (Middle)

301 CARLSON PARKWAY

SUITE 210

(Street)

MINNEAPOLIS MN 55305

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
DiaMedica Therapeutics Inc. [ DMAC ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
11/21/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	11/21/2025		M		12,000	A	$2.2(1)	87,854	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	$2.2(1)	11/21/2025		M			12,000	(2)	12/01/2025	Common Shares	12,000	$0	0	D

Explanation of Responses:

1. Represents the conversion of the exercise price from CAD$ to US$ on the transaction date.

2. Fully vested.

	/s/ Scott Kellen, attorney-in-fact	11/25/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did the DiaMedica Therapeutics (DMAC) insider transaction on 11/21/2025 involve?

An insider who is a director of DiaMedica Therapeutics Inc. exercised a stock option, acquiring 12,000 common shares on 11/21/2025.

At what price were the DiaMedica (DMAC) stock options exercised?

The stock option was exercised at an exercise price of $2.20 per share, reflecting a conversion of the original CAD$ price into US$ on the transaction date.

How many DiaMedica Therapeutics (DMAC) shares does the director own after this Form 4 transaction?

After the reported transaction, the director directly owns 87,854 common shares of DiaMedica Therapeutics Inc.

What happened to the DiaMedica (DMAC) stock option reported in Table II?

The reported stock option (right to buy) for 12,000 shares, with a $2.20 exercise price, was fully vested and exercised, and the remaining derivative securities beneficially owned are 0.

What is the relationship of the reporting person to DiaMedica Therapeutics (DMAC)?

The reporting person is identified as a Director of DiaMedica Therapeutics Inc. and filed the Form 4 as one reporting person.

Does this DiaMedica (DMAC) Form 4 involve any indirect ownership?

No. The filing shows the ownership form as Direct (D) for the 87,854 common shares held after the transaction.